Common Stock Purchase Agreement with Aspire Capital
On January 24, 2013, we entered into a Common Stock Purchase Agreement, or the Purchase Agreement, with Aspire Capital Fund, LLC, or Aspire, to purchase, at our option, up to an aggregate of $12.0 million of shares of our common stock over a two-year term, which expires in May 2015. Under the Purchase Agreement, we initially issued 132,743 shares of our common stock as a commitment fee. Our sales to Aspire will be made subject to market conditions, in light of our capital needs and under various limitations contained in the Purchase Agreement. At September 30, 2013 our closing stock price was below the floor price of $1.00 per share required by the Purchase Agreement; as a result there was no availability under this facility at September 30, 2013. We have not yet sold any shares under the Purchase Agreement.
Over the term of the Purchase Agreement, assuming the Company’s common stock is trading above the $1.00 minimum floor price that is required to use the facility, we have two ways to elect to sell common stock to Aspire on any business day we select: (1) through a regular purchase of up to 100,000 shares at prices based on the market price of our common stock prior to the time of each sale, and (2) through a volume weighted average price, or VWAP, purchase of a number of shares up to 30% of the volume traded on the purchase date at a price equal to the lesser of the closing sale price or 95% of the VWAP for such purchase date.
Change in Directors or Principal Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) On December 17, 2013, the Board of Directors (the "Board") of BG Medicine, Inc. (the "Company") approved a change to Stephane Bancel's position within the Company from Executive Chairman to Chairman, effective as of November 1, 2013. In connection with this change, the Compensation Committee of the Board of the Company terminated Mr. Bancel's consulting agreement with the Company, pursuant to which Mr. Bancel had been entitled to receive the equivalent of up to $150,000 per year in stock options for his service as Executive Chairman. Accordingly, as of November 1, 2013, Mr. Bancel (i) ceased vesting in the stock option that was granted to him on July 25, 2011 when he became Executive Chairman, the vesting of which was contingent upon him serving as Executive Chairman, and (ii) ceased receiving all other compensation set forth in his consulting agreement. In lieu thereof, effective as of November 1, 2013, Mr. Bancel became eligible to receive compensation under the Company's non-employee director compensation policy.
Anyway ( F ) Em
I know you dont want to hear that, But thats the truth.
Without support from the company, This will continue down till the earnings report, Thats a fact.
The last jump was a trading Opp. and I took full advantage of it, I sold all my shares @ $1.50 and have been buying back shares from $1.10 down to where we are now, And I will continue to buy all the way down to .74 if it hits that mark , Which I think it will.
Short term I really dont care which way this stock goes, Im in this to make $$$$$ and I will buy if it goes lower and will not sell if it goes higher, I have a price which I will dump, But all depend on the news.
The support level is .74, I will continue to buy all the way down to there,
Some year this will change LOL
Thats the question, But all kidding aside, I think .74 is the bottom,
NOT A GOOD SIGN
Un ( F ) n real
Thank god my shares are profit, Or I would be Mad as He11
I agree, I can not access TRADE ARCHITECT this morning, They have a new page to load and it wont load level ll or the launch page, Very sad what tda has done to this platform, Im going to check out scottrade to look at their platform, TDA is a pure POS to say the least
An another ( F ) n english teacher, Did I say that right ???
I could buy and sell you my boy, As we say in ""Da Bronx, Haw U Doin Hon""
There was more then one reason BGMD got delisting notice's
1 = On November 22, 2013, BG Medicine, Inc. (the "Company") received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC ("NASDAQ") indicating that, for the preceding 30 consecutive business days, the market value of the Company's publicly held shares had closed below the minimum $15,000,000 threshold for continued listing on The NASDAQ Global Market,
2 = the Company has requested a hearing before the NASDAQ Listing Qualifications Panel (the "Panel") to address its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market, as set forth in NASDAQ Listing Rule 5450(b)(2)(A).
3 = The Company also remains subject to a grace period of 180 calendar days, or until March 24, 2014, to regain compliance with the $1.00 bid price requirement for continued listing on The NASDAQ Global Market, as set forth in NASDAQ Listing Rule 5450(a)(1). As previously disclosed via a Current Report on Form 8-K filed September 27, 2013,
First nd2win let me expose you for who you really are, a lying bashing trader who dosen't know PooPoo about this stock , You're stuck now with your shares and I hope you get hammered, I'll be willing to take the loss short term just to see you get stopped out, And you will.
I on the other hand am in this to stay because Im playing with their money
But Down And thats the truth